Table 4 Comparison of clinicopathologic parameters between ER and LTS groups
Groups | ER (N = 28) | 3-year LTS (N = 28) | p vs ER | 5-year LTS (N = 20) | p vs ER |
|---|---|---|---|---|---|
Sex (female) | 22 | 23 | 1 | 17 | 0.716 |
Age (years) | 50.07 [51 (30–72)] | 57 [62(26–78)] | 0.09 | 58.7 [63 (28–78)] | 0.061 |
< 30 | 0 | 2 | 1 | ||
30–60 | 24 | 11 | 7 | ||
> 60 | 4 | 15 | 12 | ||
Continuous variables | mean (median [range]) | mean (Median [range]) | |||
BMI | 24.6 [24.2 (16.8–34.4)] | 24.4 [24 (18–37)] | 0.72 | 23.54 [23.98 (18.6–27.5)] | 0.403 |
ASA score | 0.861 | 0.859 | |||
1 | 1 | 1 | 1 | ||
2 | 22 | 23 | 16 | ||
3 | 4 | 4 | 3 | ||
4 | 1 | 0 | 0 | ||
Type of primary | 0.226 | 0.396 | |||
Breast | 18 | 17 | 13 | ||
Squamous origin | 0 | 2 | 2 | ||
Melanoma | 2 | 1 | 1 | ||
Genito-urinary | 2 | 5 | 3 | ||
Sarcoma | 2 | 3 | 1 | ||
Gastro-intestinal | 3 | 0 | 0 | ||
Esophagus | 1 | 0 | 0 | ||
Disease-free interval | 0.533 | 0.281 | |||
0–12 months | 13 | 10 | 7 | ||
12–24 months | 2 | 1 | 0 | ||
> 24 months | 13 | 17 | 13 | ||
AFC score | 0.64 | 0.727 | |||
1 | 5 | 4 | 2 | ||
2 | 2 | 4 | 4 | ||
3 | 6 | 9 | 5 | ||
4 | 9 | 4 | 4 | ||
5 | 5 | 6 | 4 | ||
6 | 1 | 1 | 1 | ||
AFC score cat | 0.422 | 0.770 | |||
Low/intermediate risk | 13/15 | 17/11 | 11/ 9 | ||
Size of metastasis at diagnosis (mm) | 37.8 [35 (12–70)] | 33 [24(10–104)] | 0.058 | 30.8 [24 (10–100)] | 0.041 |
Size of metastasis pre-op (mm) | 34.18 [34 (8–65)] | 29.6 [22(3–100)] | 0.166 | 29.4 [22 (3–100)] | 0.143 |
Diam > 50 mm | 9 | 6 | 0.547 | 4 | 0.512 |
Number of LM | 2.25 [2 (1–5)] | 2 [1(1–9)] | 0.104 | 2.25 [1 (1–9)] | 1 |
Number of LM pre-op | 2.07 [2 (1–4)] | 1.7 [1(1–9)] | 0.021 | 1.95 [1 (1–9)] | 0.792 |
Multinodular metastasis | 18 | 14 | 0.418 | 9 | 0.242 |
Positive LN status of primary | 18 | 7 | 0.002 | 5 | 0.007 |
Synchronous (< 12 months) | 13 | 10 | 0.135 | 6 | 0.370 |
mCRS | 0.132 | 0.190 | |||
0 | 3 | 7 | 6 | ||
1 | 8 | 10 | 6 | ||
2 | 5 | 7 | 5 | ||
3 | 9 | 4 | 3 | ||
4 | 3 | 0 | 0 | ||
mCRS cat | 0.037 | 0.059 | |||
Low-/high risk | 16 /12 | 24 | 17/ 3 | ||
RF | 10 | 5 | 0.371 | 3 | 0.354 |
Major hepatectomy | 7 | 7 | 1 | 5 | 1 |
Post-operative complications | 5 | 6 | 0.6 | 3 | 0.683 |
Clavien-Dindo | 0.34 | 0.195 | |||
I–II | 3 | 3 | 3 | ||
IIIa | 2 | 1 | 0 | ||
Primary | |||||
NACT | 15 | 6 | 0.026 | 6 | 0.144 |
ACT | 22 | 18 | 0.375 | 13 | 0.339 |
Hormonal therapy | 13 | 15 | 0.79 | 12 | 0.394 |
Radiotherapy | 15 | 14 | 1 | 11 | 1 |
Immunotherapy | 0.449 | 0.676 | |||
No | 19 | 18 | 13 | ||
Trastuzumab | 8 | 6 | 5 | ||
Glivec | 1 | 2 | 1 | ||
Other | 0 | 2 | 1 | ||
Liver metastasis | |||||
NACT | 24 | 23 | 1 | 17 | 1 |
ACT | 21 | 13 | 0.09 | 10 | 0.208 |